TC
DMAAR

T3 Companies’s Drugs Made In America Acquisition Corp Rights DMAAR Stock Holding History

T3 Companies’s Portfolio DMAAR Stock Details DMAAR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.65K Buy
+15,000
New +$1.55K ﹤0.01% 170

Other funds holding DMAAR

CS
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.66% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $1.14B AUM 6.91% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $15.7B AUM 36.4% 1-Year Est. Return
GCIA
Gabelli & Co Investment Advisers Rye, New York $688M AUM 63.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

T3 Companies's DMAAR Position: Q2 2026 in Review

T3 Companies opened a new position in Drugs Made In America Acquisition Corp Rights (DMAAR) in Q2 2026: 15,000 shares worth $1.65K. The stake represents ﹤0.01% of the portfolio and ranks #170 among its holdings.

9 funds tracked by Wall St. Rank hold DMAAR as of Q2 2026.

  • T3 Companies held 15,000 shares of Drugs Made In America Acquisition Corp Rights worth $1.65K as of Q2 2026.
  • Drugs Made In America Acquisition Corp Rights was a new T3 Companies position in Q2 2026.
  • Drugs Made In America Acquisition Corp Rights made up ﹤0.01% of T3 Companies's portfolio in Q2 2026, its #170 holding.
  • 9 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp Rights as of Q2 2026.

Based on T3 Companies's 13F filing for Q2 2026, filed 27 Jul 2026.